Chronic Constipation Market Set to Grow Substantially Through 2034, DelveInsight Projects

DelveInsight's "Chronic Constipation Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Chronic Constipation, historical and forecasted epidemiology as well as the Chronic Constipation market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Chronic Constipation market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Constipation Market Forecast
https://www.delveinsight.com/sample-request/chronic-constipation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Chronic Constipation Market Report:
• The Chronic Constipation market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In April 2025, Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company focused on developing transformative therapies for gastrointestinal (GI) and rare diseases, announced that following a recent discussion with the U.S. Food and Drug Administration (FDA), a confirmatory Phase 3 trial will be required to pursue approval of apraglutide for patients with short bowel syndrome (SBS) with intestinal failure (IF) who rely on parenteral support. While continuing the development of apraglutide, Ironwood has engaged Goldman Sachs & Co. LLC to evaluate strategic alternatives aimed at maximizing shareholder value.
• In January 2025, NeurAxis Inc. has obtained FDA 510(k) clearance for its Rectal Expulsion Device (RED), intended to assess and evaluate patients with chronic constipation caused by pelvic floor dyssynergia, particularly those who may not respond effectively to increased laxative therapy.
• In December 2024, NeurAxis, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Rectal Expulsion Device (RED), allowing the company to commercially offer the device for assessing and evaluating patients with chronic constipation caused by pelvic floor dyssynergia, particularly those unlikely to benefit from increased laxative therapy.
• As per Yamamoto et al. (2022), an online survey in the United States indicated a 5.5% prevalence of chronic constipation using the Rome III criteria. In Japan, the prevalence was reported to be 2.1% based on medical consultations.
• Naronapride, and other emerging therapies are giving positive topline results, in their clinical trials. These emerging therapies are in mid phase of its clinical trials and are awaiting a launchwhich will make the pipeline robust.
• Key Chronic Constipation Companies: ABBVIE, Eisai Co., Ltd., Anji Pharma, Yuhan, Renexxion Ireland, Forest Laboratories, Albireo, EA Pharma Co., Ltd., Astellas Pharma Inc, Kissei Pharmaceutical Co., Ltd., Novartis, Theravance Biopharma, SK Life Science, Inc., Movetis, Kissei Pharmaceutical Co., Ltd, Ipsen, and others
• Key Chronic Constipation Therapies: LINZESS (linaclotide), GOOFICE, ANJ908 (Pradigastat), YH12852, Naronapride, Linaclotide, A3309, AJG555, linaclotide, KWA-0711, Tegaserod, TD-5108, YKP10811, prucalopride, KWA-0711, PEG 4000 (Forlax®), and others
• The Chronic Constipation epidemiology based on gender analyzed that the prevalence of Chronic Constipation is higher in females than in males.
• The Chronic Constipation market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Constipation pipeline products will significantly revolutionize the Chronic Constipation market dynamics.

Chronic Constipation Overview
Chronic constipation refers to a persistent and long-term condition characterized by infrequent bowel movements, difficulty passing stool, and a feeling of incomplete evacuation. It is typically defined as experiencing fewer than three bowel movements per week over an extended period.

Get a Free sample for the Chronic Constipation Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/chronic-constipation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Constipation Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Constipation Epidemiology Segmentation:
The Chronic Constipation market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Chronic Constipation
• Prevalent Cases of Chronic Constipation by severity
• Gender-specific Prevalence of Chronic Constipation
• Diagnosed Cases of Episodic and Chronic Chronic Constipation

Download the report to understand which factors are driving Chronic Constipation epidemiology trends @ Chronic Constipation Epidemiology Forecast
https://www.delveinsight.com/sample-request/chronic-constipation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Constipation Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Constipation market or expected to get launched during the study period. The analysis covers Chronic Constipation market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Chronic Constipation Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Chronic Constipation Therapies and Key Companies
• LINZESS (linaclotide): ABBVIE
• GOOFICE: Eisai Co., Ltd.
• ANJ908 (Pradigastat): Anji Pharma
• YH12852: Yuhan
• Naronapride: Renexxion Ireland
• Linaclotide: Forest Laboratories
• A3309: Albireo
• AJG555: EA Pharma Co., Ltd.
• linaclotide: Astellas Pharma Inc
• KWA-0711: Kissei Pharmaceutical Co., Ltd.
• Tegaserod: Novartis
• TD-5108: Theravance Biopharma
• YKP10811: SK Life Science, Inc.
• prucalopride: Movetis
• KWA-0711: Kissei Pharmaceutical Co., Ltd
• PEG 4000 (Forlax®): Ipsen

Discover more about therapies set to grab major Chronic Constipation market share @ Chronic Constipation Treatment Landscape
https://www.delveinsight.com/sample-request/chronic-constipation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Chronic Constipation Market Drivers
• Rising prevalence of chronic idiopathic constipation (CIC) and opioid-induced constipation (OIC), especially in aging populations.
• Growing awareness and improved diagnosis of gastrointestinal motility disorders.
• Increasing adoption of prescription therapies over OTC laxatives due to need for long-term efficacy.
• Launch of new mechanism-of-action drugs (e.g., GC-C agonists, 5-HT4 agonists) improving treatment outcomes.
• Expansion of healthcare access and improved reimbursement frameworks in developed markets.

Chronic Constipation Market Barriers
• High cost of branded therapies reducing adoption in price-sensitive regions.
• Limited long-term safety data for newer pharmacological treatments.
• Patient dissatisfaction with efficacy variability and treatment adherence challenges.
• Heavy reliance on traditional OTC laxatives hindering uptake of premium therapies.
• Side effects associated with prescription drugs (e.g., diarrhea, abdominal pain).

Scope of the Chronic Constipation Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Chronic Constipation Companies: ABBVIE, Eisai Co., Ltd., Anji Pharma, Yuhan, Renexxion Ireland, Forest Laboratories, Albireo, EA Pharma Co., Ltd., Astellas Pharma Inc, Kissei Pharmaceutical Co., Ltd., Novartis, Theravance Biopharma, SK Life Science, Inc., Movetis, Kissei Pharmaceutical Co., Ltd, Ipsen, and others
• Key Chronic Constipation Therapies: LINZESS (linaclotide), GOOFICE, ANJ908 (Pradigastat), YH12852, Naronapride, Linaclotide, A3309, AJG555, linaclotide, KWA-0711, Tegaserod, TD-5108, YKP10811, prucalopride, KWA-0711, PEG 4000 (Forlax®), and others
• Chronic Constipation Therapeutic Assessment: Chronic Constipation current marketed and Chronic Constipation emerging therapies
• Chronic Constipation Market Dynamics: Chronic Constipation market drivers and Chronic Constipation market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Chronic Constipation Unmet Needs, KOL's views, Analyst's views, Chronic Constipation Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.